Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M5,640Revenue (TTM) $M366Net Margin (%)-32.6Altman Z-Score16.6
Enterprise Value $M5,031EPS (TTM) $-0.9Operating Margin %-32.9Piotroski F-Score3
P/E(ttm)--Beneish M-Score1.5Pre-tax Margin (%)-32.6Higher ROA y-yN
Price/Book8.210-y EBITDA Growth Rate %-3.7Quick Ratio5.5Cash flow > EarningsN
Price/Sales14.45-y EBITDA Growth Rate %-3.6Current Ratio6.0Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-16.9Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)-24.3Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M140ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with SGEN

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
SGENVanguard Health Care Fund 2015-12-31 Sold Out -0.01%$37.16 - $45.52
($41.72)
$ 40.24-4%Sold Out0
SGENVanguard Health Care Fund 2015-06-30 Buy 0.02%$34.03 - $49.63
($41.17)
$ 40.24-2%New holding170,125
SGENFirst Eagle Investment 2010-03-31 Sold Out -0.01%$9.34 - $12.59
($10.85)
$ 40.24271%Sold Out0
SGENFirst Eagle Investment 2009-12-31 Buy 0.01%$8.74 - $13.16
($9.69)
$ 40.24315%New holding67,373
SGENBill Gates 2009-09-30 Sold Out -0.39%$8.75 - $14.8
($11.69)
$ 40.24244%Sold Out0
SGENFirst Eagle Investment 2009-06-30 Sold Out -0.01%$8.18 - $10.34
($9.11)
$ 40.24342%Sold Out0
SGENFirst Eagle Investment 2009-03-31 Add$7.23 - $10.36
($9.4)
$ 40.24328%Add 40.00%70,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

SGEN is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


SGEN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
SIEGALL CLAY BPresident and CEO 2016-05-27Sell48,660$40.41-0.42view
SIEGALL CLAY BPresident and CEO 2016-05-24Sell8,400$40.090.37view
SIEGALL CLAY BPresident and CEO 2016-05-17Sell7,618$35.1614.45view
SIEGALL CLAY BPresident and CEO 2016-04-25Sell800$400.6view
SIEGALL CLAY BPresident and CEO 2016-04-05Sell7,618$36.1211.41view
SIEGALL CLAY BPresident and CEO 2016-03-22Sell15,236$35.5213.29view
BAKER FELIXDirector, 10% Owner 2016-03-17Buy124,065$31.8526.34view
BAKER FELIXDirector, 10% Owner 2016-03-16Buy1,349,237$32.125.36view
BAKER FELIXDirector, 10% Owner 2016-03-11Buy694,666$32.4623.97view
BAKER FELIXDirector, 10% Owner 2016-03-08Buy502,523$22.6677.58view

Quarterly/Annual Reports about SGEN:

News about SGEN:

Articles On GuruFocus.com
Insiders Roundup: Theravance Biopharma, Western Gas, Upland Software Mar 18 2016 
Top Insider Trades of the Past Week Feb 19 2016 
Insiders Are Buying Barnes & Noble Sep 18 2015 
Vanguard Health Care Fund Buys Two New Stakes in Second Quarter Aug 06 2015 
Insiders keep on buying Macerich Co and Seattle Genetics May 22 2015 
Insiders new buys : ZU, SGEN, MAC, SHLD, TBRA May 12 2015 
Seattle Genetics: Can Record Growth From Its Licenses Oct 28 2014 
Seattle Genetics: Can Record Sustained Growth From Royalty Aug 31 2014 
Will ImmunoGen’s Q4 Earnings Disappoint Again? Jul 30 2014 
Weekly CFO Sells Highlight: USB, SGEN, CAH, ALXN, ABMD Jul 21 2013 

More From Other Websites
XBI Mid-Caps: Seattle Genetics Rose Due to Higher Trading Volumes May 27 2016
Seattle Genetics Starts Trial on Acute Myeloid Leukemia Drug May 26 2016
SEATTLE GENETICS INC /WA Files SEC form 8-K, Change in Directors or Principal Officers, Submission... May 25 2016
Seattle Genetics Initiates Pivotal Phase 3 Trial of Vadastuximab Talirine (SGN-CD33A) for Patients... May 25 2016
A Scarcity of Biotech Assets for Buyouts? May 20 2016
ETF’s with exposure to Seattle Genetics, Inc. : May 19, 2016 May 19 2016
Seattle Genetics, Inc. breached its 50 day moving average in a Bullish Manner : SGEN-US : May 18,... May 18 2016
SEATTLE GENETICS INC /WA Files SEC form 8-K, Change in Directors or Principal Officers May 13 2016
SEATTLE GENETICS INC /WA Financials May 05 2016
ETF’s with exposure to Seattle Genetics, Inc. : May 4, 2016 May 04 2016
Seattle Genetics to Present at Upcoming Investor Conferences May 04 2016
Seattle Genetics gears up for big expansion of cancer drug pipeline May 02 2016
Seattle Genetics, Inc. :SGEN-US: Earnings Analysis: Q1, 2016 By the Numbers May 02 2016
Seattle Genetics’ Valuation: How Does It Compare? Apr 30 2016
Seattle Genetics, Alder BioPharmaceuticals report losses Apr 29 2016
SEATTLE GENETICS INC /WA Files SEC form 10-Q, Quarterly Report Apr 29 2016
Seattle Genetics (SGEN) Posts Wider-than-Expected Q1 Loss Apr 29 2016
Edited Transcript of SGEN earnings conference call or presentation 28-Apr-16 8:30pm GMT Apr 29 2016
Seattle Genetics reports 1Q loss Apr 28 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)